Implantation of left ventricular assist devices under extracorporeal life support in patients with heparin-induced thrombocytopenia
- 5 June 2015
- journal article
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 18 (4) , 291-299
Abstract
Heparin-induced thrombocytopenia (HIT) is a rare but life-threatening side effect of heparin therapy. It is a demanding therapeutic challenge in patients undergoing left ventricular assist device (LVAD) implantation. We present our experience with LVAD implantation under extracorporeal life support (ECLS) in patients suffering from HIT. Seven patients (mean age 54.0 ± 16.7 years, 1 female, 6 male patients) suffering from acute heart failure were stabilized with ECLS. Under heparin therapy, they all showed a sudden decrease of mean platelet count (maximum 212.6 ± 41.5 tsd/μl; minimum 30.7 ± 13.1 tsd/μl). Due to the clinical suspicion of HIT anticoagulation was switched from heparin to argatroban (aPTT 70–80 s.). No improvement of cardiac function could be detected under ECLS, so LVAD implantation was indicated. We performed LVAD implantation under ECLS. During LVAD implantation under argatroban (aPTT of 50–60 s.) one patient developed massive intraventricular thrombus formations, so the device had to be removed. In 6 cases, we could successfully perform LVAD implantation under argatroban with a higher aPTT of 70–80 s and modified operative strategy. Four patients needed postoperative re-exploration because of bleeding complications. Perioperative management of LVAD patients under argatroban anticoagulation is very difficult. We were able to minimize the perioperative risk for thrombosis with a target aPTT of 70–80 s. To keep the phase of stasis within the device as short as possible we anastomosed the VAD outflow graft to the ascending aorta first before connecting the device to the apex. However, postoperative bleeding complications are frequent.Keywords
This publication has 24 references indexed in Scilit:
- Heparin-Induced Thrombocytopenia During Extracorporeal Membrane OxygenationJournal of Cardiothoracic and Vascular Anesthesia, 2014
- Management of a Pediatric Patient on the Berlin Heart Excor Ventricular Assist Device With Argatroban After Heparin-Induced ThrombocytopeniaASAIO Journal, 2008
- Off-pump Exchange of Short-term Percutaneous Ventricular Assist Device (VAD) to Long-term Implantable VAD in Severe Coagulopathy and Multi-organ FailureThe Journal of Heart and Lung Transplantation, 2008
- Impact of Heparin-Induced Thrombocytopenia on Outcome in Patients with Ventricular Assist Device Support: Single-Institution Experience in 358 Consecutive PatientsThe Annals of Thoracic Surgery, 2007
- Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: First results from the ARG-E03 trialThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Effects of Argatroban Therapy, Demographic Variables, and Platelet Count on Thrombotic Risks in Heparin-Induced ThrombocytopeniaChest, 2006
- Heparin-induced thrombocytopenia in patients receiving mechanical circulatory supportThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic DysfunctionChest, 2006
- Importance of preoperative liver function as a predictor of survival in patients supported with Thoratec ventricular assist devices as a bridge to transplantationThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995